Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation

Neuroscience Letters
M SobradoAntonio G García

Abstract

Recent clinical trials have shown that galantamine is efficacious in the treatment of mild to moderate Alzheimer's and vascular dementia, and memantine in severe stages of these diseases. Hence, the hypothesis that these two drugs might exert different degrees of neuroprotection has been tested. Rat hippocampal slices were subjected to oxygen and glucose deprivation (OGD) and to a re-oxygenation period. Neuronal damage was monitored using the lactate dehydrogenase (LDH) released into the Krebs-bicarbonate medium as an indicator. Galantamine, a mild acetylcholinesterase (AChE) blocker and nicotinic receptor modulator, given 30 min before and during OGD plus re-oxygenation (1, 2 and 3 h) significantly reduced LDH release by around 50%. Galantamine 5 microM reduced LDH release significantly during the re-oxygenation period while at 15 microM it afforded significant reduction of LDH release both during OGD and re-oxygenation. Memantine, a reversible blocker of NMDA receptors, at 10 microM only significantly reduced (40%) LDH release after 3 h re-oxygenation. The classical NMDA blocker MK-801 reduced LDH released around 40% at 1 microM at all re-oxygenation times studied. These data indicate that galantamine has a neuroprotective wi...Continue Reading

References

Aug 1, 1991·European Journal of Clinical Chemistry and Clinical Biochemistry : Journal of the Forum of European Clinical Chemistry Societies·T ThomsenH Kewitz
Aug 21, 1990·European Journal of Pharmacology·M Seif el NasrJ Krieglstein
May 1, 1995·The Annals of Thoracic Surgery·B K SiesjöJ Folbergrová
Sep 3, 2002·Proceedings of the National Academy of Sciences of the United States of America·Simona CapsoniAntonino Cattaneo
Dec 25, 2002·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Anna RytterTadeusz Wieloch
Apr 4, 2003·The New England Journal of Medicine·Barry ReisbergUNKNOWN Memantine Study Group
Jul 23, 2003·Zeitschrift Für Naturforschung. C, a Journal of Biosciences·M TraykovaN Bojadgieva
Dec 3, 2003·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A F KurzC R Venkata Damaraju
Dec 16, 2003·Hospital Medicine·David J Findlay, Peter J Connelly
Dec 31, 2003·Cell·Michelle AartsMichael Tymianski

❮ Previous
Next ❯

Citations

Aug 4, 2012·ACS Chemical Neuroscience·Laura González-LafuenteCristóbal de Los Ríos
Oct 31, 2009·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·P J ModregoM Sarasa
Nov 29, 2007·Expert Opinion on Investigational Drugs·Mercedes VillarroyaManuela G López
Sep 19, 2007·Expert Opinion on Emerging Drugs·Paul A Lapchak, Dalia M Araujo
Apr 10, 2012·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Run-Ping LiKai Xiao
Jan 17, 2012·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Juan Antonio López-VillodresJosé Antonio González-Correa
Mar 24, 2009·Journal of the Neurological Sciences·Seyed Khosrow TayebatiFrancesco Amenta
Jul 5, 2006·The European Journal of Neuroscience·Christiane VolbrachtMarcel Leist
Jan 11, 2005·Brain Research Bulletin·Hugo Geerts
Oct 19, 2006·European Journal of Pharmacology·Camilo OrozcoManuela G López
Sep 29, 2006·Bioorganic & Medicinal Chemistry·José Marco-ContellesMercedes Villarroya
Jul 2, 2008·American Journal of Alzheimer's Disease and Other Dementias·Pedro J ModregoManuel Sarasa
May 3, 2006·Cerebrovascular Diseases·Eduardo Martínez-VilaPablo Irimia
Apr 25, 2008·Critical Reviews in Toxicology·Edward J Calabrese
May 29, 2007·The Journal of Pharmacology and Experimental Therapeutics·Silvia LorrioManuela G López
Nov 21, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Hélène N DavidJacques H Abraini
Oct 11, 2005·The Journal of Pharmacology and Experimental Therapeutics·C M HernandezA V Terry
Jul 1, 2020·Current Behavioral Neuroscience Reports·Maju Mathew KoolaAnilkumar Pillai
Sep 29, 2020·Neural Regeneration Research·Hilda MartInez-CoriaHéctor E López-Valdés
Jan 13, 2006·Chemical Reviews·José Marco-ContellesAntonio G García
Jun 26, 2010·Journal of Medicinal Chemistry·Cristóbal de Los RíosAlejandro Romero

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.